Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation
I'm PortAI, I can summarize articles.
Procept Biorobotics Corporation has unveiled an investor presentation emphasizing its Aquablation Therapy as a next-generation solution for benign prostatic hyperplasia (BPH). This automated waterjet technology aims to cater to various prostate sizes while enhancing safety and efficacy compared to traditional surgical methods. The presentation highlights a significant market opportunity, with over 8 million patients treated and a U.S. surgical market exceeding $20 billion. It also critiques pharmaceutical therapies for their limited symptom relief and potential side effects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments